



Contact: CEOcast, Inc.  
Gary Nash  
Investor Relations  
212-732-4300  
gnash@ceocast.com

## **ImmunoCellular Therapeutics To Present at Rodman and Renshaw's 11th Annual Healthcare Conference on Friday, September 11th**

**LOS ANGELES, CA – September 3, 2009** – ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB) (IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it will present at the Rodman and Renshaw 11th Annual Healthcare Conference on Friday September 11, 2009 at 2 p.m. eastern time at the New York Palace Hotel in New York City. IMUC's President and Chief Executive Officer, Manish Singh, Ph.D., will present an overview of the company's business and strategy at the event, which last year featured more than 500 presenting companies and 3,500 attendees.

A webcast of this presentation will be available live and by replay. To access both the live and archived webcasts, as well as the slide presentation used during the conference, please go to <http://www.wsw.com/webcast/rrshq15/imuc.ob>.

### About ImmunoCellular Therapeutics

IMUC is a Los Angeles-based clinical-stage company that is developing immune based therapies for the treatment of brain and other cancers. IMUC's lead product candidate-a dendritic cell-based vaccine for treating brain tumors-is currently being evaluated in a Phase I clinical trial. The company's "off the shelf" therapeutic vaccine product candidate targeting cancer stem cells for multiple cancer indications is expected to enter clinical trials during the second quarter of 2009. IMUC is in pre-clinical development of a monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery using differential immunization for diagnosing and treating multiple types of cancer. To learn more about IMUC, please visit [www.imuc.com](http://www.imuc.com).

###